©The Author(s) 2025.
World J Hepatol. Sep 27, 2025; 17(9): 107671
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.107671
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.107671
Figure 3 Hypoxia-induced exosomal release of glypican-3 and its effects on hepatocellular carcinoma progression and angiogenesis.
Under hypoxic conditions, hepatocellular carcinoma cells upregulate glypican-3 expression and release it via exosomes, contributing to tumor progression and angiogenesis in the tumor microenvironment. GPC3: Glypican-3; HCC: Hepatocellular carcinoma; EMT: Epithelial-mesenchymal transition.
- Citation: Wu CS, Lee TY, Chao HW. Targeting glypican-3 as a new frontier in liver cancer therapy. World J Hepatol 2025; 17(9): 107671
- URL: https://www.wjgnet.com/1948-5182/full/v17/i9/107671.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i9.107671